Anaplastic thyroid carcinoma is a sporadic malignancy; no causative germline genes are certified in this packet, and no hereditary inheritance pattern is documented. The condition arises from undifferentiated epithelial cells within the thyroid gland. Molecular alterations in individual tumors represent somatic events. Some cases may occur in the context of a pre-existing differentiated thyroid neoplasm.

Diagnosis is established through pathological evaluation of thyroid tissue demonstrating undifferentiated cells with evidence of epithelial differentiation on immunohistochemistry or electron microscopy. The characteristic histological pattern includes a mixture of spindle, epithelioid, and giant cells. Clinical imaging characterizes the extent of the rapidly enlarging neck mass and assesses involvement of adjacent respiratory, musculature, and skeletal structures. Pathological confirmation is required for definitive diagnosis.

No FDA-approved treatments for thyroid gland undifferentiated (anaplastic) carcinoma are certified in this packet. Two agents have received FDA orphan drug designation for this indication: autologous CAR T cells targeting intercellular adhesion molecule-1 / ICAM-1 (AffyImmune Therapeutics) and combretastatin A4 phosphate (Mateon Therapeutics), both currently under investigation and not approved for clinical use. A third agent, vemurafenib, previously held an orphan drug designation for anaplastic thyroid carcinoma, but that designation was subsequently withdrawn. Multiple investigational therapeutic approaches are being evaluated in active clinical trials, encompassing drug therapy, biologic therapy, and other modalities.

Long-term prognosis data beyond the disease definition are not certified in this packet. The disease definition characterizes the clinical course as usually aggressive, with rapid progression a recognized feature. Individual outcome data are not certified in this packet.

Multiple active clinical trials are investigating therapeutic approaches for anaplastic thyroid carcinoma. Certified active studies include a trial evaluating trametinib in combination with paclitaxel (NCT03085056, Phase 1/early), a study of cemiplimab combined with dabrafenib and trametinib (NCT04238624, Phase 2), a Phase 2 trial of pembrolizumab in metastatic or locally advanced anaplastic/undifferentiated thyroid cancer (NCT05119296), a Phase 2 study of nivolumab plus lenvatinib (NCT05696548), a Phase 2 trial of avutometinib and defactinib in thyroid cancer (NCT06007924), and a Phase 2 immunotherapy combination study including anaplastic thyroid cancer (NCT06790706). Additional Phase 1 and Phase 2 studies are also active. The published research landscape encompasses 173 classified articles, with basic science and preclinical research representing the dominant category alongside 37 review articles.